TSS
VIR icon

Two Sigma Securities’s Vir Biotechnology VIR Stock Holding History

Two Sigma Securities’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,368
Closed -$67.4K – 2034
2025
Q2 		$67.4K Buy
+13,368
New +$71.7K 0.01% 1086

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Securities's VIR Position: Q3 2025 in Review

Two Sigma Securities sold out of Vir Biotechnology (VIR) in Q3 2025, closing a stake of 13,368 shares — an estimated $67.4K sold.

Two Sigma Securities first reported a position in VIR in Q2 2025 and held it in 1 quarter. The position peaked at $67.4K in Q2 2025. 213 funds tracked by Wall St. Rank hold VIR as of Q3 2025.

  • Two Sigma Securities reported no remaining Vir Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Securities sold 13,368 Vir Biotechnology shares in Q3 2025, an estimated $67.4K.
  • Two Sigma Securities first reported a position in Vir Biotechnology in Q2 2025 and held it in 1 quarter.
  • Two Sigma Securities's Vir Biotechnology position peaked at $67.4K in Q2 2025.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.